RMC No. 93-2024: Updates to VAT-Exempt Medicines Following FDA Letter on TRAIN and CREATE Acts

RMC No. 93-2024 publishes FDA-endorsed updates to the VAT-exempt list of medicines under TRAIN and CREATE Acts, including additions and deletions, effective upon FDA publication. Businesses and tax practitioners handling pharmaceuticals must review the updated VAT-exempt list as endorsed by the Food and Drug Administration (FDA) and published by the Bureau of Internal Revenue. This […]

RMC No. 156-2022: Updates to VAT-Exempt Medicines List for Common and Chronic Illnesses

RMC No. 156-2022 updates the VAT-exempt medicines list under the CREATE Act, covering chronic and life-threatening conditions. Businesses must adjust VAT calculations immediately. Businesses and healthcare providers must now adjust their VAT calculations immediately for certain medicines prescribed for hypertension, diabetes, high cholesterol, tuberculosis, mental illness, and cancer. The Food and Drug Administration’s latest update, […]

RMC No. 129-2022: Updates to VAT-Exempt Medicines List Affecting Mental Health Prescriptions

RMC No. 129-2022 updates the VAT-exempt medicines list under the CREATE Act, removing certain mental health medicines and requiring businesses to apply 12% VAT immediately. Businesses in the pharmaceutical sector, healthcare providers, and distributors must take immediate note: certain medicines previously exempt from VAT under Republic Act No. 11534 (CREATE Act) are now removed from […]

RMC No. 119-2022: VAT Exemption for Newly Endorsed COVID-19 Medicines

RMC No. 119-2022 adds Nirmatrelvir + Ritonavir 150 mg + 100 mg tablets for COVID-19 to the VAT-exempt list, effective from FDA publication, impacting healthcare providers and distributors. Businesses and healthcare providers must update their VAT-exempt inventory immediately: the Food and Drug Administration has added Nirmatrelvir + Ritonavir 150 mg + 100 mg film-coated tablets […]

RMC No. 112-2022: FDA-Endorsed Updates to VAT-Exempt Medicines Affecting Tuberculosis Treatments

RMC No. 112-2022 updates the VAT-exempt medicines list under the CREATE Act, adding tuberculosis medicines and removing COVID-19 medicines, affecting tax compliance for healthcare providers. Businesses in the pharmaceutical and healthcare sectors must immediately update their records and compliance processes due to the newly endorsed changes to the VAT-exempt medicines list. Certain medicines prescribed for […]

RMC No. 103-2021: Updated List of VAT-Exempt Medicines and COVID-19 Drugs for Immediate Compliance

RMC No. 103-2021 publishes updated VAT-exempt lists of medicines for hypertension, cancer, kidney diseases, and COVID-19 drugs, requiring immediate compliance for affected businesses. Businesses and taxpayers dealing with pharmaceutical products and COVID-19 treatments must immediately review the updated VAT-exempt lists published by the FDA and DOH. This update, under RMC No. 103-2021, supplements prior guidelines […]